Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 01 Jul 2024

Comparison of 68Ga-FAP-2286 and 18F-FDG PET/CT in the diagnosis of advanced lung cancer

in Cancer Molecular Targets and Therapeutics

Feifan Xiang
Yue Zhang
Xiaoqi Tan
Jintao Zhang
Tengfei Li
Yuanzhuo Yan
Wenzhe Ma
Yue Chen

Frontiers in Oncology

doi 10.3389/fonc.2024.1413771

1,925 views
1 citation

Original Research

Published on 01 Jul 2024

Pharmacological inhibition of CDK4/6 impairs diffuse pleural mesothelioma 3D spheroid growth and reduces viability of cisplatin-resistant cells

in Cancer Molecular Targets and Therapeutics

Aurora Costa
Iris Maria Forte
Francesca Pentimalli
Carmelina Antonella Iannuzzi
Luigi Alfano
Francesca Capone
Rosa Camerlingo
Alessandra Calabrese
Claudia von Arx
Reyes Benot Dominguez

Frontiers in Oncology

doi 10.3389/fonc.2024.1418951

2,072 views
4 citations

Review

Published on 24 Jun 2024

Assessment of KRASG12C inhibitors for colorectal cancer

in Cancer Molecular Targets and Therapeutics

Gary A. Piazza
Preethi Chandrasekaran
Yulia Y. Maxuitenko
Karim I. Budhwani

Frontiers in Oncology

doi 10.3389/fonc.2024.1412435

3,740 views
3 citations

Mini Review

Published on 17 Jun 2024

Non-immune functions of B7-H3: bridging tumor cells and the tumor vasculature

in Cancer Molecular Targets and Therapeutics

Shuo Wu
Chenxi Hu
Kaiyuan Hui
Xiaodong Jiang

Frontiers in Oncology

doi 10.3389/fonc.2024.1408051

1,922 views
2 citations

Review

Published on 12 Jun 2024

MUC21: a new target for tumor treatment

in Cancer Molecular Targets and Therapeutics

Miao Li
Hui Li
Ting Yuan
Zhi Liu
Yukun Li
Yingzheng Tan
Yunzhu Long

Frontiers in Oncology

doi 10.3389/fonc.2024.1410761

2,565 views
1 citation

Case Report

Published on 12 Jun 2024

Case report: Innovative treatment for one metastatic thyroid-like follicular carcinoma of the kidney with ATM and POLE mutations

in Cancer Molecular Targets and Therapeutics

Jin-Ju Lei
Jie Rao
Hong-Yan Feng
De-Dong Cao
Hong-Lin Yan
Jing-Ping Yuan
Zhen-Min Jiang
Yi-Qiao Zhang

Frontiers in Oncology

doi 10.3389/fonc.2024.1352865

1,340 views

Original Research

Published on 12 Jun 2024

Auranofin and reactive oxygen species inhibit protein synthesis and regulate the level of the PLK1 protein in Ewing sarcoma cells

in Cancer Molecular Targets and Therapeutics

Joseph A. Haight
Stacia L. Koppenhafer
Elizabeth L. Geary
David J. Gordon

Frontiers in Oncology

doi 10.3389/fonc.2024.1394653

1,197 views

Editorial

Published on 11 Jun 2024

Editorial: Editor's challenge: Dr. Qingxin Mu - how can nanomedicine approaches advance multi-targeting strategy in combination cancer therapy?

in Cancer Molecular Targets and Therapeutics

Marina Pinheiro
Qingxin Mu

Frontiers in Oncology

doi 10.3389/fonc.2024.1437497

596 views

Case Report

Published on 10 Jun 2024

Case report: Ipilimumab and nivolumab in metastatic adrenocortical cancer with high tumor mutational burden

in Cancer Molecular Targets and Therapeutics

Rebekka Mispelbaum
Tessa Hattenhauer
Franz-Georg Bauernfeind
Jan-Frederic Lau
Peter Brossart
Annkristin Heine

Frontiers in Oncology

doi 10.3389/fonc.2024.1406616

1,000 views
1 citation

Brief Research Report

Published on 30 May 2024

Blockade of tumor cell-intrinsic PD-L1 signaling enhances AURKA-targeted therapy in triple negative breast cancer

in Cancer Molecular Targets and Therapeutics

Andrew Takchi
Minzhi Zhang
Mohammad Jalalirad
Roberto Leon Ferre
Royal Shrestha
Tufia Haddad
Jann Sarkaria
Ann Tuma
Jodi Carter
Hillman David

Frontiers in Oncology

doi 10.3389/fonc.2024.1384277

2,473 views
1 citation

Mini Review

Published on 28 May 2024

Advances in CAR-NK cell therapy for lung cancer: is it a better choice in the future?

in Cancer Molecular Targets and Therapeutics

Fengqin Liu
Xia Miao
Lu Han
Xiao Song

Frontiers in Oncology

doi 10.3389/fonc.2024.1390006

3,771 views
2 citations

Review

Published on 28 May 2024

Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies

in Cancer Molecular Targets and Therapeutics

Nating Xiong
Heming Wu
Zhikang Yu

Frontiers in Oncology

doi 10.3389/fonc.2024.1405491

10,094 views
25 citations

Perspective

Published on 24 May 2024

Immunotherapy and stereotactic body radiotherapy for older patients with non-metastatic renal cancer unfit for surgery or decline nephrectomy: practical proposal by the International Geriatric Radiotherapy Group

in Cancer Molecular Targets and Therapeutics

Nam P. Nguyen
Monica-Emilia Chirila
Brandi R. Page
Vincent Vinh-Hung
Olena Gorobets
Mohammad Mohammadianpanah
Huan Giap
Meritxell Arenas
Marta Bonet
Pedro Carlos Lara

Frontiers in Oncology

doi 10.3389/fonc.2024.1391464

2,267 views

Editorial

Published on 23 May 2024

Editorial: Novel therapeutic targets of gastric carcinogenesis: from basic research to drug development and clinical application

in Cancer Molecular Targets and Therapeutics

Chenchen Niu
Dong Ren
Bella Lingjia Liu

Frontiers in Oncology

doi 10.3389/fonc.2024.1431520

629 views

Mini Review

Published on 22 May 2024

Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance

in Cancer Molecular Targets and Therapeutics

Jameela Lokhandwala
Tracess B. Smalley
Timothy H. Tran

Frontiers in Oncology

doi 10.3389/fonc.2024.1394702

4,956 views
6 citations

Original Research

Published on 17 May 2024

The HER2 flip-HER2 amplification of tumor cells in the cerebrospinal fluid of breast cancer patients with leptomeningeal disease: implications for treating the LM tumor with anti-HER2 therapy

in Cancer Molecular Targets and Therapeutics

Priya U. Kumthekar
Barbara Blouw
Perry Corkos
Seema Nagpal
Arushi Tripathy
David Piccioni
Michael Youssef

Frontiers in Oncology

doi 10.3389/fonc.2024.1402651

1,361 views
6 citations